MedTrace Logo

MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients

NCT06044493 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2026-04-15

No results posted yet for this study

Summary

The purpose of this study is to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients after Kidney Transplant Recipients

Conditions

  • Kidney Transplant

Interventions

DRUG

Myreptic-N Tablet

Up to 720mg BID(total 1440mg daily), PO - Check the blood concentration of Mycophenolate at each visit

DRUG

Mycophenolate mofetil Tablet/Capsule

Up to 1g BID(total 2g daily), PO - Check the blood concentration of Mycophenolate at each visit

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Jongwon Ha, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-14
Primary Completion
2025-10-29
Completion
2025-10-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06044493 on ClinicalTrials.gov